WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported striking preclinical results for its experimental oral drug ...
WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
(RTTNews) - Aclaris Therapeutics, Inc. (ACRS) Wednesday announced positive top-line results from the Phase 2b ATI-1777-AD-202 study of ATI-1777 in patients with mild to severe atopic dermatitis. The ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: Aclaris Therapeutics Inc.
WAYNE, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results